Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
2081-2100 of 3,900 trials

Distal Radius Fracture: Brachial Plexus Nerve Block

We are studying whether an ultrasound-guided nerve block helps adults with distal radius fractures manage pain better than standard treatment during closed reduction. This trial will assess both the benefits and potential risks.

Distal Radius Fracture>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesInternal MedicineNeurologyOrthopedics and Traumatology

Colorectal Polypectomy: Anticoagulation Study

We are investigating whether continuing blood-thinning medication during polypectomy is safe for patients. The goal is to see if it helps reduce the risk of blood clots during the procedure.

Patients on Anticoagulants for Colonoscopy>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesPartially RemoteGastroenterologyHematology

Futibatinib Safety Study for Cancer Patients

We are collecting long-term safety information for patients who previously benefited from futibatinib treatment. This study helps ensure that continuing the medication remains safe for them.

Malignant Solid Tumors1-2 yearsEfficacy phase (II)Confirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesOncology

Metastatic Melanoma: Early Detection of Side Effects

We are investigating whether a special imaging technique can help identify early side effects in patients receiving immune therapy for metastatic melanoma. This study aims to improve monitoring of immune-related side effects.

Malignant Melanoma>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesOncology

Ependymoma Treatment: SIOP Ependymoma II Program

We are exploring new chemotherapy options and surgical techniques for children and young adults with ependymoma. Our goal is to improve survival rates and treatment effectiveness compared to standard methods.

Ependymoma>2 yearsEfficacy phase (II)Confirmation phase (III)No PlaceboInvestigational MedicinesOncologyPediatrics

Small Cell Lung Cancer: Durvalumab Immunotherapy

We are studying whether durvalumab can help frail patients with limited small cell lung cancer live longer without disease progression after receiving thoracic chemoradiotherapy. The trial also examines the treatment's safety and its effects on quality of life.

Limited Stage Small Cell Lung Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Takayasu Arteritis: Infliximab vs. Tocilizumab

We are studying whether Infliximab is more effective than Tocilizumab for patients with refractory or relapsing Takayasu arteritis. The goal is to see if it helps reduce disease activity and steroid use.

Takayasu's Arteritis>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesCardiologyRheumatology

Glibenclamide for High Blood Sugar in Premature Infants

We are studying whether an oral suspension of glibenclamide can help control high blood sugar in premature infants under 1500 grams. The trial will also look at its safety and effects on growth.

Neonatal Hyperglycemia>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesEndocrinologyPediatrics

Non-Ischemic Dilated Cardiomyopathy: SECRET-HF Treatment

We are exploring whether infusions of a cell-derived product can improve heart function in patients with non-ischemic dilated cardiomyopathy. This study aims to find new treatment options for this condition.

Non-ischemic Dilated Cardiomyopathy>2 yearsSafety phase (I)Cardiology

Primary Hyperoxaluria: DCR-PHXC Injection Study

We are evaluating a new injection for patients with Primary Hyperoxaluria to see how it affects kidney function and overall safety. The study also looks at its impact on kidney stones and quality of life.

Primary Hyperoxaluria>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteEndocrinologyNephrology

Advanced Solid Tumors: ORIC-114 Study

We are testing a new drug, ORIC-114, for patients with advanced solid tumors that have EGFR or HER2 alterations. The study will assess its safety and effectiveness alone and with chemotherapy.

Solid Tumors3-6 monthsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesOncology

Cataract Surgery: Preoperative NSAIDs Study

We are comparing how different medication regimens affect inflammation after cataract surgery. This study aims to find the best approach to improve recovery for patients.

Cataract1-2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesOphthalmology

Multiple Myeloma: SABLe Study with Selinexor

We are investigating a new treatment combination for patients with newly diagnosed multiple myeloma who cannot have a transplant. The study aims to evaluate how well the treatment works and its effects on quality of life.

Multiple Myeloma>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteHematologyOncology

Triple Negative Breast Cancer: Sacituzumab Govitecan and Pembrolizumab Study

We are testing a new treatment combination for patients with triple negative breast cancer who have residual disease after surgery. The study aims to see if this combination improves survival compared to standard treatment options.

Triple Negative Breast Cancer3-6 monthsConfirmation phase (III)16-20 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteOncology

Multiple Sclerosis: Siponimod Therapy Study

We are exploring how siponimod affects inflammation in patients with active secondary progressive multiple sclerosis. The study aims to understand its impact on disease progression and patient health over time.

Progressive Multiple Sclerosis>2 yearsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesNeurology

Advanced Lung Cancer: Amivantamab and Lazertinib Study

We are exploring a new treatment combination for people with advanced non-small cell lung cancer who have an EGFR mutation and have not responded to earlier therapies. The goal is to see if this combination can improve treatment outcomes and safety.

Advanced Non-Small Cell Lung Cancer (NSCLC)1-2 yearsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesPartially RemoteOncologyPulmonology

Chronic Low Back Pain: Tricortin 1000 Study

We are testing Tricortin 1000 to see if it helps relieve pain better than a placebo and an existing treatment for chronic low back pain. This study aims to improve pain management for those experiencing acute flare-ups.

Low Back Pain≤3 monthsMonitoring phase (IV)≤5 visitsInvestigational MedicinesInternal MedicineOrthopedics and Traumatology

Major Depressive Disorder: Liposom Forte with Citalopram

We are studying whether Liposom Forte can enhance and speed up the response to citalopram in elderly patients with Major Depressive Disorder. The trial also looks at the safety of this treatment.

Major Depression3-6 monthsMonitoring phase (IV)6-10 visitsStandard MedicinesPsychiatry

Advanced Colorectal Cancer: pTTL Immunotherapy

We are testing a new T cell immunotherapy called pTTL for patients with advanced colorectal cancer. This study aims to see how well it works and its safety in humans.

Colorectal Cancer>2 yearsSafety phase (I)Oncology

Head and Neck Cancer: Carboplatin, Paclitaxel, and Cetuximab Study

We are studying a combination of three medications for patients with recurrent or metastatic head and neck squamous cell carcinoma who did not respond to previous treatments. The goal is to see if this combination improves response rates and overall survival.

Head and Neck Cancer3-6 monthsEfficacy phase (II)No PlaceboStandard MedicinesPartially RemoteOncology